inflAmmatory maRkers in Blood and Thrombus Aspirated From Patients With acutE myocaRdial Infarction With St-segment elevAtion

NCT01757886 | Unknown

• 1 other identifier: ARTERIA-2012
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 3

Brief Summary

The prognostic value of inflammatory markers in acute coronary syndrome has been extensively demonstrated, however it is still unknown whether there is an association between circulating and local (thrombus) inflammatory molecules, and the subset of molecules that provide better prognostic information in patients with ST-elevation acute coronary syndrome.

Conditions

Patients Admitted With the Diagnosis of ST-elevation Acute Coronary Syndrome

Keywords

Myocardial infarction, Inflammation, Thrombus, Coronary angioplasty.

Outcome Measures

Primary Outcomes (1)

• The primary objective of the study is to find out whether there is an association between certain inflammatory markers in blood and intracoronary thrombus and whether these markers are associated with the composite of all-cause mortality

  one year

Study Arms (1)

ST-elevation acute coronary syndrome

ARTERY is a prospective, multicenter, which will include patients admitted with the diagnosis of ST-elevation acute coronary syndrome and thrombus aspiration is performed during primary angioplasty

Other: Biomarkers to analyze both intracoronary thrombi as blood

Interventions

Biomarkers to analyze both intracoronary thrombi as blood OTHER

ST-elevation acute coronary syndrome

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Pilot, prospective cohort, which included all patients admitted with a diagnosis of ST-elevation myocardial infarction and undergoing thrombus aspiration during a procedure effective emerging percutaneous coronary revascularization.

You may qualify if:

• They include patients of both sexes, without limits of age, with a diagnosis of STEMI within 12 hours after the beginning of symptoms. ST-elevation myocardial infarction was defined in the presence of symptoms consistent, persistent elevation (\> 20 min) ST segment ≥ 1 mm in at least two contiguous leads or in the presence of left bundle branch block presumably new onset and cardiac troponin I elevation

You may not qualify if:

• Injury significant common core of left coronary artery (stenosis greater than or equal to 50% of the vessel lumen).
• Pre-Fibrinolysis percutaneous coronary intervention.
• Previous coronary bypass surgery.
• Thyrotoxicosis.
• Having an inflammatory systemic or local inflammatory process.
• Malignant neoplasm.
• Any disease that seriously compromise the prognosis and / or systemic inflammatory response generated.
• No thrombotic material obtained in the thrombus or insufficient for performing biochemical determinations.

Sponsors & Collaborators

• Fundación Canaria Rafael Clavijo para la Investigación Biomédica: lead

Study Sites (3)

Hospital Universitario de Canarias

San Cristóbal de La Laguna, Santa Cruz de Tenerife, E-38320, Spain

RECRUITING

Hospital Universitario de Canarias

San Cristóbal de La Laguna, Santa Cruz de Tenerife, E-38320, Spain

RECRUITING

Hospital Universitario de Canarias

San Cristóbal de La Laguna, Tenerife, 38320, Spain

RECRUITING

MeSH Terms

Conditions

Myocardial Infarction; Inflammation; Thrombosis

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis; Embolism and Thrombosis

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Alberto Dominguez-Rodriguez, MD, PhD

  Hospital Universitario de Canarias

  STUDY CHAIR

Central Study Contacts

Alberto Dominguez-Rodriguez, MD, PhD

CONTACT

+34 922 679040; adrvdg@hotmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Alberto Dominguez Rodriguez

Study Record Dates

• First Submitted: December 22, 2012
• First Posted: December 31, 2012
• Study Start: November 1, 2012
• Primary Completion: November 1, 2012
• Study Completion: November 1, 2013
• Last Updated: December 31, 2012

Record last verified: 2012-12

Locations

ES (3)